Group 1: Management and Talent Development - The company has been continuously attracting high-end talent to enhance the management team's structure and capabilities, aiming for sustainable development [1] - The management team is expected to further strengthen talent development initiatives [1] Group 2: Medical Aesthetics Progress - The clinical trial for the "recombinant type III humanized collagen freeze-dried fibers" has been completed, and the company is preparing to submit registration materials [1] Group 3: E-commerce Operations - The e-commerce team is divided into interest e-commerce and shelf e-commerce, with operations based in Shanghai and Hangzhou respectively [2] - The Shanghai team focuses on platforms like Douyin, while the Hangzhou team manages Tmall operations [2] Group 4: Sales Performance and Promotions - The performance during the 3.8 promotional period met expectations, with a focus on daily sales [2] - The company anticipates that the 3.8 promotional activities will positively impact overall performance [2] Group 5: New Product Development - The company plans to continue a dual approach in new product development, focusing on medical devices and functional skincare products [2] - New product forms will include dressings, masks, lotions, creams, and serums, with specifics to be confirmed in 2026 [2] Group 6: Pricing and Cost Management - Product pricing has remained stable, with fluctuations within a reasonable range during promotional periods [2] - The company employs refined operational strategies to control online business costs while enhancing profitability [2] Group 7: Dividend Policy - The dividend proposal for the current year has not yet been determined, with an announcement expected on April 23, 2026 [2]
敷尔佳(301371) - 2026年3月10日投资者关系活动记录表（一）